Le Lézard
Classified in: Health
Subjects: EXE, WOM, STP, MAT

U.S. Supreme Court denies review of SF crisis pregnancy law, ordinance stands, reports Herrera


SAN FRANCISCO, June 28, 2018 /PRNewswire-USNewswire/ -- City Attorney Dennis Herrera issued the following statement after the U.S. Supreme Court today let stand lower court rulings upholding San Francisco's ordinance that prevents anti-abortion centers from engaging in false or misleading advertising:

San Francisco City Attorney's Office's official seal. Dennis Herrera, City Attorney. (PRNewsFoto/City Attorney of San Francisco)

"This case was about the truth. Now the truth prevails. These so-called crisis pregnancy centers engaged in insidious and deceptive practices to trick women in decisions about their bodies. These groups are entitled to be advocates, but they're not entitled to break the law. False and misleading advertising by these clinics is a deceitful practice that preys on women when they least suspect it.

The delays these centers can cause interfere with women's time-sensitive, constitutionally protected right to choose what is best for them. Reproductive rights are human rights. They must be protected now more than ever."

Case Background
Supervisor Malia Cohen introduced legislation in 2011 prohibiting limited-services pregnancy centers in San Francisco from making false or misleading statements to the public about pregnancy-related services that the centers offer. While some so-called crisis pregnancy centers openly acknowledge their pro-life advocacy, many misleadingly target women in search of abortion services though false advertising ? and then employ manipulative and fear-mongering tactics on their visitors to dissuade them from obtaining abortions. Crisis pregnancy centers commonly offer few services other than anti-abortion rhetoric, but the proliferation of Internet search engines has given anti-abortion centers an effective way to misrepresent themselves as bona fide clinics, offering prominent paid links in response to search queries for "abortion," "emergency contraception" and related terms within their region.

First Resort Inc., whose stated goal is "to build an abortion-free world," sued San Francisco in 2011 over the City's advertising ordinance. First Resort alleged that the ordinance was a violation of their free speech rights. A federal judge upheld the ordinance in 2015, and the U.S. 9th Circuit Court of Appeals upheld it in 2017, noting that the ordinance regulated only unprotected commercial speech and was valid under the First Amendment.  The U.S. Supreme Court today denied First Resort's appeal of that ruling.

The case is First Resort Inc. v Dennis J. Herrera, U.S. Supreme Court Case No. 17-1087. Additional documentation from the case is available on the City Attorney's website at: www.sfcityattorney.org

SOURCE City Attorney of San Francisco


These press releases may also interest you

at 18:05
Celltrion partners with TV star Mollie Pearce to launch the second installation of the Where's Crohn's & Colitis (CC)? campaign for this year's World IBD Day (19 May 2024). The campaign focuses on access to IBD care and treatment as the burden of...

at 14:06
On Wednesday, May 15, Red Door Community hosted their annual Celebrating Women Working and Living with Cancer Luncheon at the Metropolitan Club in New York City. The event raised more than $300,000 while shining a light on the women who inspire us...

at 14:05
Product: Kalihim (Philippine Bread Roll) Issue: Food - Allergen - Egg Distribution: British Columbia See the affected products and product photos for this recall SOURCE Canadian Food Inspection Agency (CFIA)

at 13:27
The global industrial automation market in life sciences industry  size is estimated to grow by USD 5.06 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of  11.4%  during the forecast period. ...

at 11:03
Boston Scientific Corporation today announced positive six-month results from the ongoing pivotal MODULAR ATP clinical trial of the mCRMtm System,* the first modular cardiac rhythm management (CRM) system that consists of the EMBLEMtm Subcutaneous...

at 08:35
Gilead Sciences, Inc. , following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements...



News published on and distributed by: